KRAS-mutant pancreatic ductal adenocarcinoma (PDAC)

Clinical trials for KRAS-mutant pancreatic ductal adenocarcinoma (PDAC) explained in plain language.

Never miss a new study

Get alerted when new KRAS-mutant pancreatic ductal adenocarcinoma (PDAC) trials appear

Sign up with your email to follow new studies for KRAS-mutant pancreatic ductal adenocarcinoma (PDAC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Trials to join now! 1

New pill targets Hard-to-Treat KRAS cancers in first human trial

Disease control Recruiting now

This early-phase trial is testing an experimental oral drug called KST-6051 in adults with advanced or metastatic solid tumors that have a KRAS mutation, including certain lung, pancreatic, and colorectal cancers. The main goal is to check the drug's safety and how the body proce…

Matched conditions: KRAS-MUTANT PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)

Phase 1 • Sponsor: Kestrel Therapeutics, Inc. • Aim: Disease control

Last updated Jul 01, 2026 00:00 UTC

KRAS-mutant pancreatic ductal adenocarcinoma (PDAC)

Get alerted when new KRAS-mutant pancreatic ductal adenocarcinoma (PDAC) trials appear

New pill targets Hard-to-Treat KRAS cancers in first human trial